UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2023 |
INOZYME PHARMA, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware | 001-39397 | 38-4024528 | ||
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||
|
|
|
|
|
321 Summer Street Suite 400 |
| |||
Boston, Massachusetts |
| 02210 | ||
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (857) 330-4340 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
| Trading |
|
|
Common stock, par value $0.0001 per share |
| INZY |
| Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On June 13, 2023, the Board of Directors (the “Board”) of Inozyme Pharma, Inc. (the “Company”) approved an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately. The amendments effected by the Amended and Restated Bylaws, among other things:
The Amended and Restated Bylaws also include various other updates, including certain technical, conforming and clarifying changes. The foregoing description of the Amended and Restated Bylaws is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the Company's annual meeting of stockholders held on June 13, 2023, the Company’s stockholders voted on the following proposals:
1. | The following three nominees were elected to the Board as Class III directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders. The results of the stockholders’ votes with respect to the election of such Class III directors were as follows: |
|
| Votes For |
| Votes Withheld |
| Broker Non-Votes |
Martin Edwards |
| 18,800,004 |
| 9,699,208 |
| 8,241,716 |
Lynne Sullivan |
| 27,636,274 |
| 862,938 |
| 8,241,716 |
Douglas Treco |
| 28,377,236 |
| 121,976 |
| 8,241,716 |
2. | The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified. The results of the stockholders’ votes with respect to such ratification were as follows: |
Votes For: | 36,729,818 | ||
Votes Against: | 10,739 | ||
Votes Abstaining: | 371 | ||
Broker Non-Votes: |
|
| — |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit | Description | |
3.1 |
| |
104 | Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
| INOZYME PHARMA, INC. |
|
|
|
|
Date: | June 14, 2023 | By: | /s/ Douglas A. Treco |
|
|
| Name: Douglas A. Treco |